Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796220 · ClinicalTrials.gov registry record · Phase 1
Focused Ultrasound and Gemcitabine in Breast Cancer
A Phase 1 study of Breast Cancer and Breast Neoplasms, sponsored by Patrick Dillon, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04796220 is a Phase 1 study of Breast Cancer and Breast Neoplasms that is actively recruiting participants, run by Patrick Dillon, MD. The registered enrollment target is 32 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04796220, a Phase 1 study of Breast Cancer and Breast Neoplasms, is actively recruiting participants, sponsored by Patrick Dillon, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We will be testing the effects of each of these regimens on cells in the immune system. We hypothesize that the combination of focused ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will increase T cell activity. We also hypothesize that focused ultrasound ablation and low-dose gemcitabine will be safe and will result in non-inferior surgical completion rates and tumor margin assessments.
Conditions Studied
Interventions
- DEVICE Focused Ultrasound
- OTHER Gemcitabine and Focused Ultrasound
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2030-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04796220
The ClinicalTrials.gov registry entry for NCT04796220 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Patrick Dillon, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Focused Ultrasound is the first listed.
NCT04796220 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04796220 about?
NCT04796220 is a clinical study titled "Focused Ultrasound and Gemcitabine in Breast Cancer". This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We will be testing the effects of each of these regimens on cells in the immune...
What is the current status of trial NCT04796220?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-01-27. Estimated completion is 2030-02.
What conditions does trial NCT04796220 study?
This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms.
What interventions are being tested in trial NCT04796220?
The interventions under investigation include: Focused Ultrasound (DEVICE), Gemcitabine and Focused Ultrasound (OTHER).
Who is sponsoring clinical trial NCT04796220?
This trial is sponsored by Patrick Dillon, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04796220 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.